The search for an HIV vaccine, the journey continues

Dieffenbach, Carl W.; Fauci, Anthony S.

doi:10.1002/jia2.25506

Cited by 14 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 193 − 195 AIDSVAX was not successful after phase III trials 196 , 197 in the US, while RV144 was the subject of further trials in Thailand but has not been approved due to limited efficacy. 187 , 194 …”

Section: Peptides For Vaccines For Infectious Diseasesmentioning

confidence: 99%

Peptides for Vaccine Development

Hamley

2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

This review discusses peptide epitopes used as antigens in the development of vaccines in clinical trials as well as future vaccine candidates. It covers peptides used in potential immunotherapies for infectious diseases including SARS-CoV-2, influenza, hepatitis B and C, HIV, malaria, and others. In addition, peptides for cancer vaccines that target examples of overexpressed proteins are summarized, including human epidermal growth factor receptor 2 (HER-2), mucin 1 (MUC1), folate receptor, and others. The uses of peptides to target cancers caused by infective agents, for example, cervical cancer caused by human papilloma virus (HPV), are also discussed. This review also provides an overview of model peptide epitopes used to stimulate non-specific immune responses, and of self-adjuvanting peptides, as well as the influence of other adjuvants on peptide formulations. As highlighted in this review, several peptide immunotherapies are in advanced clinical trials as vaccines, and there is great potential for future therapies due the specificity of the response that can be achieved using peptide epitopes.

show abstract

Section: Peptides For Vaccines For Infectious Diseasesmentioning

confidence: 99%

Peptides for Vaccine Development

Hamley

2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

show abstract

“…In the absence of an approved vaccine to prevent HIV‐1 transmission (Laher et al, 2020; Medlock et al, 2017), and despite the great efforts made by researchers during recent years (Baden et al, 2020; Dieffenbach & Fauci, 2020; Pantaleo et al, 2019; Pitisuttithum & Marovich, 2020), combined antiretroviral therapy (cART) remains the primary strategy to treat and control HIV‐1 infection (Giacomelli et al, 2019; Phanuphak & Gulick, 2020). However, cART is costly and poses a challenge to apply in low‐resource countries (Kahn et al, 2011).…”

Section: The Importance Of Vaginal Microbicides To Prevent Hiv‐1mentioning

confidence: 99%

Baseline and time‐updated factors in preclinical development of anionic dendrimers as successful anti‐HIV‐1 vaginal microbicides

Rodriguez-Izquierdo

Sepúlveda‐Crespo

Lasso³

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Although a wide variety of topical microbicides provide promising in vitro and in vivo efficacy, most of them failed to prevent sexual transmission of human immunodeficiency virus type 1 (HIV-1) in human clinical trials. In vitro, ex vivo, and in vivo models must be optimized, considering the knowledge acquired from unsuccessful and successful clinical trials to improve the current gaps and the preclinical development protocols. To date, dendrimers are the only nanotool that has advanced to human clinical trials as topical microbicides to prevent HIV-1 transmission. This fact demonstrates the importance and the potential of these molecules as microbicides. Polyanionic dendrimers

show abstract

“…The RV144 trial (Thia trial) that combined two failed vaccines, recombinant Canarypox vector ALVAC-HIV (vCP1521) and AIDSVAX (B/E), failed to show sufficient efficacy for approval by the Thailand Ministry of Health [ 174 ]. In 2019, the National Institutes of Health announced phase III clinical trials of Imbokodo (HVTN705/HPX2008) in women in Southern Africa and Mosaico (HVTN706/HPX3002) in men and transgender persons to evaluate vaccine efficacy [ 51 ]. The Ad26-based mosaic vaccine, containing Evn, reverse transcriptase Pol, and capsid protein Geg, showed 100 % immune response in humans when combined with high-dose of gp140 boost [ 13 ].…”

Section: Acquired Immunodeficiency Syndromementioning

confidence: 99%

Peptides to combat viral infectious diseases

Al-Azzam¹,

Ding

Liu

et al. 2020

Peptides

View full text Add to dashboard Cite

Highlights Five viral infectious diseases with high global prevalence are discussed. Those diseases include influenza, CHB, AIDS, SARS, and COVID-19. The complicated life cycle and rapid genetic mutations of viruses demand novel medicines. Potential of peptides in therapy, vaccine, and diagnostic of viral infection diseases are addressed. Peptide-based candidates in pre-clinical and clinical stages are highlighted.

show abstract

The search for an HIV vaccine, the journey continues

Cited by 14 publications

References 16 publications

Peptides for Vaccine Development

Peptides for Vaccine Development

Baseline and time‐updated factors in preclinical development of anionic dendrimers as successful anti‐HIV‐1 vaginal microbicides

Peptides to combat viral infectious diseases

Contact Info

Product

Resources

About